Next Article in Journal
Potential Geographic Range of the Endangered Reed Parrotbill Paradoxornis heudei under Climate Change
Next Article in Special Issue
Polyherbal and Multimodal Treatments: Kaempferol- and Quercetin-Rich Herbs Alleviate Symptoms of Alzheimer’s Disease
Previous Article in Journal
Humanin and Its Pathophysiological Roles in Aging: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biology
Volume 12
Issue 4
10.3390/biology12040559
biology-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Adenosine Improves Mitochondrial Function and Biogenesis in Friedreich's Ataxia Fibroblasts Following L-Buthionine Sulfoximine-Induced Oxidative Stress

by
Sze Yuen Lew
1,†,
Nur Shahirah Mohd Hisam
1,†,
Michael Weng Lok Phang
1,
Syarifah Nur Syed Abdul Rahman
2,
Rozaida Yuen Ying Poh
3,
Siew Huah Lim
4,
Mohd Amir Kamaruzzaman
5,
Sze Chun Chau
6,
Ka Chun Tsui
6,
Lee Wei Lim
6,* and
Kah Hui Wong
1,6,*
1
Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
2
Department of Oral and Craniofacial Sciences, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur 50603, Malaysia
3
Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
4
Department of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia
5
Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Cheras, Kuala Lumpur 56000, Malaysia
6
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biology 2023, 12(4), 559; https://doi.org/10.3390/biology12040559
Submission received: 20 February 2023 / Revised: 25 March 2023 / Accepted: 30 March 2023 / Published: 6 April 2023
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: Physiology and Drug Discovery of Neurodegenerative Diseases)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Friedreich’s ataxia is the most common form of inherited ataxia, with an estimated prevalence of 1:50,000 in Caucasians. With no cure and a reduced lifespan, Friedreich’s ataxia is a devastating neurodegenerative disease. At the present time, the treatment strategies are aimed at specific symptoms, such as supportive treatment and physical therapy for motor dysfunction. Medication could improve the symptoms. However, side effects may include intolerable nausea, insomnia, and/or depression. The lack of effective therapeutic options remains a major gap in the field. Mitochondrial dysfunction and oxidative stress have been implicated in the pathogenesis of Friedreich’s ataxia. Here, we investigated the protective effects of adenosine against mitochondrial impairment in Friedreich’s ataxia. We showed that adenosine attenuated the deleterious effects of oxidative stress and mitochondrial dysfunction by regulating mitochondrial function and biogenesis in fibroblasts derived from a Friedreich’s ataxia patient. It serves as a promising therapeutic associated with mitochondrial dynamics that could eventually be a major breakthrough in the treatment of Friedreich’s ataxia, ultimately improving the quality of life of Friedreich’s ataxia patients and their caregivers and reducing its associated healthcare burden.

Abstract

Adenosine is a nucleoside that is widely distributed in the central nervous system and acts as a central excitatory and inhibitory neurotransmitter in the brain. The protective role of adenosine in different pathological conditions and neurodegenerative diseases is mainly mediated by adenosine receptors. However, its potential role in mitigating the deleterious effects of oxidative stress in Friedreich’s ataxia (FRDA) remains poorly understood. We aimed to investigate the protective effects of adenosine against mitochondrial dysfunction and impaired mitochondrial biogenesis in L-buthionine sulfoximine (BSO)-induced oxidative stress in dermal fibroblasts derived from an FRDA patient. The FRDA fibroblasts were pre-treated with adenosine for 2 h, followed by 12.50 mM BSO to induce oxidative stress. Cells in medium without any treatments or pre-treated with 5 µM idebenone served as the negative and positive controls, respectively. Cell viability, mitochondrial membrane potential (MMP), aconitase activity, adenosine triphosphate (ATP) level, mitochondrial biogenesis, and associated gene expressions were assessed. We observed disruption of mitochondrial function and biogenesis and alteration in gene expression patterns in BSO-treated FRDA fibroblasts. Pre-treatment with adenosine ranging from 0–600 µM restored MMP, promoted ATP production and mitochondrial biogenesis, and modulated the expression of key metabolic genes, namely nuclear respiratory factor 1 (NRF1), transcription factor A, mitochondrial (TFAM), and NFE2-like bZIP transcription factor 2 (NFE2L2). Our study demonstrated that adenosine targeted mitochondrial defects in FRDA, contributing to improved mitochondrial function and biogenesis, leading to cellular iron homeostasis. Therefore, we suggest a possible therapeutic role for adenosine in FRDA.

Graphical Abstract

1. Introduction

Friedreich’s ataxia (FRDA) is a degenerative autosomal recessive cerebellar ataxia, causing movement disorder. Patients with FRDA suffer from progressive gait and limb ataxia, weakness of the lower limbs, lack of tendon reflexes in the legs, dysarthria, hypertrophic cardiomyopathy, scoliosis, diabetes mellitus, and skeletal deformities [1]. Early-onset patients often become wheelchair-bound at a median of 11.5 years after onset [2]. These patients have a reduced life expectancy. Cardiac dysfunctions, including dilated cardiomyopathy and arrhythmia, are the most common cause of death in FRDA [3]. FRDA is the most common inherited cerebellar ataxia in individuals of Western European origin, with a prevalence between 1:20,000 and 1:725,000. It is also found in those of North African and Middle Eastern origin, but it has not been reported in other ethnic groups [4].
FRDA is caused by the expansion of guanine–adenine–adenine (GAA) trinucleotide repeats in the first intron of the frataxin (FXN) gene on chromosome 9q21.11, leading to substantially decreased levels of mitochondrial protein FXN [5]. Reduced FXN level causes increased cellular oxidative stress and impairs the formation of iron–sulfur (Fe-S) clusters such as heme, electron transport chain complexes I-III, and aconitase of the Krebs cycle [6]. Frataxin deficiency has been reported to impair the regulation of iron in the formation of Fe-S clusters, resulting in iron accumulation in mitochondria [7,8,9]. Excessive iron accumulation in the mitochondrial matrix causes the generation of reactive oxygen species (ROS) via the Fenton reaction and, therefore, increases oxidative stress and inactivates mitochondrial enzymes [10,11]. Disrupted mitochondrial enzyme activity leads to decreased mitochondrial respiration and production of adenosine triphosphate (ATP), resulting in mitochondrial energy imbalance and mitochondrial dysfunction [12,13].
Adenosine is a nucleoside that is widely distributed in the central nervous system (CNS) and acts as a central excitatory and inhibitory neurotransmitter in the brain [14]. It has multiple roles, including regulation of neurotransmitter release from synaptic vesicles [15,16], neuronal hyperpolarization or depolarization [17,18], and glial cell activity [19]. Increased production of extracellular adenosine has been found to play a distinct role in intercellular signaling by engaging cell surface adenosine receptors during myocardial ischemia–reperfusion injury and hypoxia and inflammation in acute respiratory distress syndrome and chronic lung diseases [14]. Although short-lived in circulation, adenosine exerts its action through activation of specific G-protein-coupled receptors, for which four subtypes (adenosine A1 receptor, A1R; adenosine A2A receptor, A2AR; adenosine A2B receptor, A2BR; and adenosine A3 receptor, A3R) have been identified so far [20,21]. However, interaction with adenosine receptors depends on disease type, location of lesion, and distribution of receptors [14]. Several CNS diseases, including cerebral ischemia [22], Alzheimer’s disease, depression [23], and epilepsy, are associated with decreased expression of A1R and increased expression of A2AR [24]. Kao et al. [25] and Lee et al. [26] also postulated that reduced levels of adenosine may cause neurological impairments in Huntington’s and Alzheimer’s disease, respectively.
To date, only one A2AR antagonist, namely istradefylline (KW6002), has been approved by the US Food Drug and Administration (FDA) as an adjuvant treatment with levodopa or carbidopa for patients with Parkinson’s disease [27,28]. Nevertheless, the therapeutic efficacy of adenosine-related treatments for many neurological and neurodegenerative diseases remains inconclusive [29].
In the past two decades, there has been scant evidence elucidating the protective effects of adenosine against cerebellar ataxia. Heffer et al. [30] showed that behavioral profiling of adenosine agonists is related to their affinity for A1R and A2R, similar to that of dopamine antagonists in the attenuation of spontaneous locomotor activity in mice. On the other hand, the cerebellar adenosinergic system involving A1R had been shown to promote ethanol- [31] and cannabinoid-induced [32,33] motor incoordination, whereas A1R antagonist attenuated the effect, suggesting modulation by an endogenous A1R. However, the mechanism of accentuation of motor incoordination by N6-cyclohexyladenosine, an A1R-selective agonist, was not investigated in the study. Moreover, Dar and Mustafa [34] found that antisense oligodeoxynucleotide targeting A1R significantly decreased the protein level of A1R.
The current study aims to bridge the research gap between the reported therapeutic effects of adenosine and the involvement of mitochondrial function and biogenesis in FRDA. Here, we investigated the protective effects of adenosine against mitochondrial dysfunction and impaired mitochondrial biogenesis in L-buthionine sulfoximine (BSO)-induced oxidative stress in dermal fibroblasts derived from an FRDA patient.

2. Materials and Methods

2.1. Chemicals and Reagents

Reagents used in this study include Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA); fetal bovine serum (FBS) (Biosera, Nuaillé, France); idebenone, L-buthionine sulfoximine (BSO), and aconitase assay kit (Cayman Chemical, Ann Arbor, MI, USA); adenosine, penicillin–streptomycin, and mitochondrial membrane potential (MMP) kit (Sigma-Aldrich, St. Louis, MO, USA); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Alfa Aesar, Haverhill, MA, USA); Mitochondrial ToxGloTM assay kit (Promega Corporation, Madison, WI, USA); MitoBiogenesis™ In-Cell ELISA Kit (Abcam, Cambridge, UK); TRIzol® reagent (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA); RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA); qPCRBIO SyGreen Mix Separate-ROX (PCR Biosystems, London, UK); and OmniPur® water (Merck Millipore, Darmstadt, Germany).

2.2. Dermal Fibroblasts Culture

Dermal fibroblasts from a healthy 33-year-old male (GM02673) and dermal fibroblasts from a 30-year-old FRDA male patient (GM04078) were purchased from Coriell Institute for Medical Research (Camden, NJ, USA) under the terms of the Material Transfer Agreement (Assurance Form) with the Universiti Malaya, with Dr. Kah Hui Wong as the principal investigator. Both dermal fibroblasts from the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository have been collected under Institutional Review Board (IRB) approval, and patient informed consent. The species of origin and molecular characterization of the fibroblasts were confirmed by Coriell Institute for Medical Research via microsatellite analysis and nucleoside phosphorylase isoenzyme electrophoresis. The FRDA fibroblasts are homozygous for GAA expansion in the FXN gene with alleles of approximately 541 and 420 repeats. Dermal fibroblasts were maintained in DMEM supplemented with 15% (v/v) FBS and 1% (v/v) penicillin–streptomycin at 37 ± 2 °C in a 5% CO2-humidified incubator according to a previous protocol [35]. Fibroblasts in DMEM without any treatment or pre-treated with 5 μM idebenone [36] served as the negative and positive controls, respectively. Idebenone, an analog of coenzyme Q10, has been used as an antioxidant therapy for the management of hypertrophic cardiomyopathy in patients with FRDA [37]. Prior to the assays, the medium was changed to phenol red-free and sodium pyruvate-free DMEM.

2.3. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Viability Assay

The normal and FRDA fibroblasts were plated at a density of 1 × 104 cells per well in a 96-well plate and incubated for 24 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The medium was replaced with a fresh medium containing adenosine ranging from 0 to 2000 µM for 24 h. Fibroblasts in DMEM without any treatment served as the negative control. After incubation, 0.5 mg/mL MTT solution was added to each well and incubated for 4 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The reduction of MTT from a yellow tetrazolium dye to purple formazan crystals can be used to measure cellular enzymes in viable cells. The medium was then removed, and dimethyl sulfoxide (DMSO) was added to each well. Absorbance was measured at 570 nm with 630 nm as background absorbance using a multimode microplate reader (SpectraMax® M3, Molecular Devices, Union City, CA, USA). The cell viability was expressed as a percentage of the negative control level.
As FRDA fibroblasts are lacking in frataxin, the cells are extremely sensitive to BSO-induced oxidative stress compared to normal fibroblasts. Frataxin has been shown to be influential in the production of Fe-S cluster-containing proteins [35]. We observed a dose-response curve of viability of normal and FRDA fibroblasts following exposure to varying concentrations of BSO for 24 h. The viability of FRDA fibroblasts decreased gradually as the concentration of BSO increased from 1.56 to 6.25 mM, with a sharp decrease in viability at 12.50 mM BSO. Large-scale death of FRDA fibroblasts was markedly pronounced by challenging the cells with 12.50 mM BSO, by which the viability was reduced to 37.47 ± 0.23%. On the other hand, 12.50 mM BSO produced mild cytotoxicity effects in normal fibroblasts with a viability of 84.81 ± 5.62% [38]. As 12.50 mM BSO produced more than 50% reduction (p < 0.05) in the viability of FRDA fibroblasts, the concentration was selected for the subsequent assays of mitochondrial function and mitochondrial biogenesis to induce oxidative stress in FRDA fibroblasts. Normal fibroblasts were not tested for these assays.

2.4. Mitochondrial Membrane Potential (MMP) Assay

The FRDA fibroblasts were plated at a density of 1 × 104 cells per well in a 96-well black plate and incubated for 24 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The medium was replaced with a fresh medium containing adenosine ranging from 0 to 800 µM or 5 µM idebenone and incubated for 2 h, followed by 12.50 mM BSO [38] for 24 h. Fibroblasts in DMEM without any treatment or pre-treated with 5 μM idebenone [36] served as the negative and positive controls, respectively. The MMP was quantified in terms of the permeability of JC-10 dye using the MMP kit according to the manufacturer’s protocol. Fluorescence intensities were measured using a multimode microplate reader (SpectraMax® M3, Molecular Devices, Union City, CA, USA) at 540 and 590 nm (red fluorescence) and 490 and 525 nm (green fluorescence) as the excitation and emission wavelengths, respectively. The ratio of red to green fluorescence intensity was expressed as a percentage of the negative control level.

2.5. Aconitase Assay

The FRDA fibroblasts were plated at a density of 1 × 105 cells per well in a 6-well plate and incubated for 24 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The medium was replaced with a fresh medium containing adenosine ranging from 0 to 600 µM or 5 µM idebenone and incubated for 2 h, followed by 12.50 mM BSO [38] for 24 h. Fibroblasts in DMEM without any treatment or pre-treated with 5 μM idebenone [36] served as the negative and positive controls, respectively. Fibroblasts were homogenized in an assay buffer and centrifuged at 800× g for 10 min at 4 °C to obtain the supernatant. Aconitase activity was determined using the aconitase assay kit according to the manufacturer’s protocol. Absorbance was measured at 450 nm using a multimode microplate reader (SpectraMax® M3, Molecular Devices, Union City, CA, USA). The activity was expressed as a percentage of the negative control level.

2.6. Adenosine Triphosphate (ATP) Assay

The FRDA fibroblasts were plated at a density of 1 × 104 cells per well in a 96-well white plate and incubated for 24 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The medium was replaced with a fresh medium containing adenosine ranging from 0 to 600 µM or 5 µM idebenone and incubated for 2 h, followed by 12.50 mM BSO [38] for 24 h. Fibroblasts in DMEM without any treatment or pre-treated with 5 μM idebenone [36] served as the negative and positive controls, respectively. The ATP content was determined using the Mitochondrial ToxGloTM assay kit according to the manufacturer’s protocol. Luminescence signal was measured using a multimode microplate reader (SpectraMax® M3; Molecular Devices, Union City, CA, USA). The activity was expressed as a percentage of the negative control level.

2.7. Mitochondrial Biogenesis Assay

The FRDA fibroblasts were plated at a density of 1 × 104 cells per well in a 96-well plate and incubated for 24 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The medium was replaced with a fresh medium containing adenosine ranging from 0 to 600 µM or 5 µM idebenone and incubated for 2 h, followed by 12.50 mM BSO [38] for 24 h. Fibroblasts in DMEM without any treatment or pre-treated with 5 μM idebenone [36] served as the negative and positive controls, respectively. Mitochondrial biogenesis was determined using the MitoBiogenesis™ In-Cell ELISA Kit according to the manufacturer’s protocol. Absorbance was measured at 405 and 650 nm for COX1 and SDH-A, respectively, using a multimode microplate reader (SpectraMax® M3; Molecular Devices, Union City, CA, USA). The activity was expressed as a ratio of SDH-A to COX1.

2.8. Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR)

The FRDA fibroblasts were plated at a density of 1 × 105 cells per well in a 6-well plate and incubated for 24 h at 37 ± 2 °C in a 5% CO2-humidified incubator. The medium was replaced with a fresh medium containing adenosine ranging from 0 to 600 µM or 5 µM idebenone and incubated for 2 h, followed by 12.50 mM BSO [38] for 24 h. Fibroblasts in DMEM without any treatment or pre-treated with 5 μM idebenone [36] served as the negative and positive controls, respectively. Fibroblasts were subjected to total RNA extraction using TRIzol® reagent according to the manufacturer’s protocol. The concentration of total RNA was determined using the NanoDrop™ 2000/2000c Spectrophotometers (Thermo Fisher Scientific, Waltham, MA, USA). Approximately 300 ng of total RNA was converted to cDNA using RevertAid First Strand cDNA Synthesis Kit according to the manufacturer’s protocol and Veriti® 96-Well Thermal Cycler (Applied Biosystems Inc., Foster City, CA, USA). The RT-qPCR was performed using 15 ng/µL cDNA template in a pooled solution containing qPCRBIO SyGreen Mix Separate-ROX, 10 pmol/µL forward and reverse oligonucleotide primers, and OmniPur® water. The primer sequences used in this study were synthesized by Genewiz (South Plainfield, NJ, USA), as shown in Table 1. Amplification was performed for 40 cycles in the StepOne Plus™ Real-Time PCR System (Applied Biosystems Inc., Foster City, CA, USA) [39,40,41]. The expression of the gene of interest was normalized to the reference gene actin beta (ACTB). Fold change of gene expression was determined using the comparative threshold cycle method (ΔΔCt) [42,43].

2.9. Statistical Analysis

All statistical analyses were performed in Statistical Package for the Social Science (SPSS) 22.0, and data were presented as mean ± standard deviation (SD) from three independent biological replicates (n = 3). The Shapiro–Wilk test was employed to evaluate the normality of the data. Normally distributed data from more than two experimental groups were examined by Levene’s test to evaluate the homogeneity of variances between groups. All groups with equal variances assumed were evaluated by one-way analysis of variance (ANOVA) to examine differences between groups, followed by Tukey’s honestly significant difference (HSD) post-hoc test. All groups with equal variances not assumed were evaluated by ANOVA, followed by Games–Howell multiple comparison post-hoc test. A statistical difference of p < 0.05 was considered significant.

3. Results

3.1. Effects of Adenosine on the Viability of Normal and FRDA Fibroblasts

Prior to the investigation of the protective effects of adenosine, the viability of adenosine-treated normal and FRDA fibroblasts was determined to exclude possible cytotoxic and proliferative effects. Fibroblasts were exposed to various concentrations of adenosine. As shown in Figure 1, the viability of normal and FRDA fibroblasts gradually decreased with increasing concentration of adenosine from 0 to 2000 µM. As the relatively lower concentrations of 0 to 800 µM adenosine showed no significant difference in the viability compared to the negative control (p > 0.05), these concentrations were selected to investigate its protective effects against mitochondrial dysfunction and impaired mitochondrial biogenesis in FRDA fibroblasts challenged with 12.50 mM BSO.

3.2. Effects of Adenosine on the Mitochondrial Membrane Potential (MMP) in FRDA Fibroblasts Treated with BSO

The MMP plays an important part in the energy storage process during oxidative phosphorylation. We used JC-10 dye to discriminate energized and de-energized mitochondria, indicated by red fluorescent aggregates in energized mitochondria with increasing membrane potential and by green fluorescence monomers in cells with mitochondria with collapsed MMP that fail to retain the dye. As shown in Figure 2, FRDA fibroblasts treated with 12.50 mM BSO showed significantly decreased MMP of 87.86 ± 2.8% or 1.1-fold lower compared to the negative control (p < 0.05). However, pre-treatment with 0 to 800 µM adenosine significantly increased MMP (104.77 ± 3.0%, 101.94 ± 4.4%, 100.66 ± 0.7%, and 101.77 ± 2.9%, respectively) to 1.1- to 1.2-fold higher compared to BSO (p < 0.05). All tested concentrations of adenosine exhibited 1.2- to 1.3-fold higher MMP compared to idebenone (p < 0.05). As the relatively lower concentrations of 0 to 600 µM adenosine showed higher MMP compared to 800 µM adenosine, these concentrations were selected in the subsequent assays of mitochondrial function and biogenesis.

3.3. Effects of Adenosine on the Aconitase Activity in FRDA Fibroblasts Treated with BSO

Aconitase is an Fe-S protein in the Krebs cycle that catalyzes the isomerization of citrate to isocitrate. As shown in Figure 3, FRDA fibroblasts treated with 12.50 mM BSO showed significantly decreased aconitase activity of 59.33 ± 11.2% or 1.7-fold lower compared to the negative control (p < 0.05). Pre-treatment with adenosine ranging from 0 to 600 µM failed to restore the depleted aconitase activity (p > 0.05). However, pre-treatment with 400 and 600 µM adenosine resulted in 1.4- to 1.5-fold higher activity compared to idebenone (p > 0.05).

3.4. Effects of Adenosine on the Adenosine Triphosphate (ATP) Level in FRDA Fibroblasts Treated with BSO

The ATP is the source of energy for use and storage at the cellular level. As shown in Figure 4, FRDA fibroblasts treated with 12.50 mM BSO showed a significantly decreased ATP level of 74.83 ± 3.2% or 1.3-fold lower compared to the negative control (p < 0.05). However, pre-treatment with 200 µM adenosine increased the ATP level to 85.45 ± 4.7% or 1.1-fold higher compared to BSO (p < 0.05). All tested concentrations of adenosine exhibited 179.1- to 203.5-fold higher ATP levels compared to idebenone (p < 0.05).

3.5. Effects of Adenosine on the Mitochondrial Biogenesis in FRDA Fibroblasts Treated with BSO

Mitochondrial biogenesis is the growth and division of pre-existing mitochondria. In this study, mitochondrial biogenesis was evaluated by the ratio of two mitochondrial proteins, namely succinate dehydrogenase subunit A (SDH-A), a subunit of complex II (nuclear DNA, nDNA-encoded) and cytochrome c oxidase subunit 1 (COX1), a subunit of complex IV (mitochondrial DNA, mtDNA-encoded). As shown in Figure 5, there was no significant difference in the SDH-A/COX1 ratio between negative control and FRDA fibroblasts treated with 12.50 mM BSO (p > 0.05). However, pre-treatment with 400 and 600 µM adenosine significantly increased the ratio to 109.77 ± 3.5% and 108.32 ± 4.6% or 1.2-fold higher compared to BSO, respectively (p < 0.05). All tested concentrations of adenosine exhibited a 2.1- to 2.2-fold higher SDH-A/COX1 ratio compared to idebenone (p < 0.05).

3.6. Effects of Adenosine on the Gene Expression Associated with Mitochondrial Biogenesis in FRDA Fibroblasts Treated with BSO

The NRF1 modulates mitochondrial biogenesis by binding to specific promoter sites and regulating the expression of TFAM. As shown in Figure 6A, FRDA fibroblasts treated with 12.50 mM BSO showed significantly increased expression of NRF1 or 2.6-fold higher compared to the negative control (p < 0.05). However, pre-treatment with 400 and 600 µM adenosine significantly decreased the expression of NRF1 to 1.3- and 1.5-fold lower compared to BSO, respectively (p < 0.05). All tested concentrations of adenosine exhibited 8.8- to 11.6-fold lower expression of NRF1 compared to that of idebenone (p < 0.05).
The TFAM, an nDNA-encoded mtDNA-binding protein, is required for the regulation of mtDNA transcription, replication, and maintenance. As shown in Figure 6B, FRDA fibroblasts treated with 12.50 mM BSO significantly increased the expression of TFAM or 3.1-fold higher compared to the negative control (p < 0.05). However, pre-treatment with 400 and 600 µM adenosine significantly decreased the expression of TFAM to 1.3- and 1.5-fold lower compared to BSO, respectively (p < 0.05). All tested concentrations of adenosine exhibited 4.0- to 4.6-fold lower expression of TFAM compared to that of idebenone (p < 0.05).
The PPARGC1A is the master regulator of mitochondrial biogenesis and energy expenditure. It modulates the activity of transcription factors, including NRF1. As shown in Figure 6C, there was no significant difference in the expression of PPARGC1A between the negative control and FRDA fibroblasts treated with 12.50 mM BSO (p > 0.05). Pre-treatment with adenosine ranging from 0 to 600 µM did not decrease the expression of PPARGC1A compared to BSO (p > 0.05). All tested concentrations of adenosine exhibited 20.6- to 37.7-fold lower expression of PPARGC1A compared to that of idebenone (p < 0.05).
The NFE2L2 is a major transcription factor that regulates the expression of various antioxidant genes, redox homeostasis, and anti-inflammatory and metabolic enzymes. Additionally, NFE2L2/antioxidant response element (ARE) signaling cascade has been observed to activate mitochondrial biogenesis. As shown in Figure 6D, FRDA fibroblasts treated with 12.50 mM BSO significantly increased the expression of NFE2L2 or 13.5-fold higher compared to the negative control (p < 0.05). However, pre-treatment with 400 and 600 µM adenosine significantly decreased the expression of NFE2L2 to 1.5- and 79.6-fold lower compared to BSO, respectively (p < 0.05). Adenosine (600 µM) exhibited a 21.2-fold lower expression of NFE2L2 compared to that of idebenone (p < 0.05).

4. Discussion

In this study, we investigated the protective effects of adenosine against BSO-induced oxidative stress in an in vitro model of FRDA using fibroblasts derived from an FRDA patient. Our aim was to elucidate the mechanism of action in which adenosine can exert its antioxidant potential through the involvement of mitochondrial function and biogenesis and associated gene expression patterns following oxidative stress.
The key pathophysiological features of FRDA include excessive iron accumulation in the mitochondrial matrix, mitochondrial dysfunction, mitochondrial energy imbalance due to decreased ATP production, and increased sensitivity to oxidative stress [12]. Currently, there is no FDA-approved treatment to halt the progression of FRDA [44]. Various pharmacological agents and natural products targeting oxidative stress [45,46,47,48,49,50,51] have been considered in the management of neuromuscular disorders, including FRDA [38,52,53]. Adenosine and its derivatives have been reported to exhibit free radical scavenging activities [54] and protect bone marrow-derived neural stem cells against hydrogen peroxide (H2O2)-induced oxidative stress and apoptosis [55].
Based on in vitro and in vivo studies, idebenone has been widely portrayed as a potent antioxidant [56,57], facilitating the redox flux of the mitochondrial electron transport chain to generate cellular ATP through oxidative phosphorylation. Idebenone was assigned Orphan Drug Status (EU/3/04/189) by the European Commission on 8 March 2004 for the treatment of cognitive and behavioral deficits, FRDA, and Leber’s hereditary optic neuropathy (LHON). Further, idebenone reduced impaired respiratory function in patients with Duchenne muscular dystrophy [58]. The QS10, a metabolite of idebenone, has been found to act as a replacement for endogenous CoQ10 in CoQ10-deficient cells and as a nutraceutical support to bypass complex I deficiency in LHON and autosomal dominant optic atrophy [59,60]. Idebenone has been observed to act as an antioxidant in preventing lipid peroxidation and rupturing of mitochondrial membrane function and as an electron carrier in supporting mitochondrial function and promoting ATP production in pre-clinical models [37,61,62,63,64,65] and clinical trials [66,67,68,69,70] of FRDA.
We observed that adenosine ranging from 0 to 800 µM did not cause cytotoxicity in normal and FRDA fibroblasts. Such a conclusion was also reached by Barth et al. [71], Jennings et al. [72], and Qi et al. [15]. Adenosine up to 500 µM did not induce cytotoxicity in cultured organotypic hippocampal slices [71] and normal human dermal fibroblasts [72]. Qi et al. [15] found that the effect of adenosine was concentration-dependent and saturated at 500 µM in suppressing excitatory transmission in layer 4 of the rat barrel cortex. Interestingly, 100 μM adenosine has been shown to maintain inflammasome activity and increase the duration of the inflammatory response through cAMP/PKA/CREB/HIF-1α pathway and A2AR, respectively, in mice deficient in Il1r, Nlrp3, Asc, P2X7, and caspase-1 primed with lipopolysaccharide [73].
The relative MMP in living cells can be a direct measurement of mitochondrial function. Excessive ROS production induces rapid depolarization of MMP and damages mitochondrial proteins and enzymes, leading to impaired oxidative phosphorylation and disrupted ATP generation [74]. Adenosine is a purine metabolite essential for the synthesis of ATP, the main energy source for cellular metabolism [75]. We observed that FRDA fibroblasts treated with BSO demonstrated reduced MMP, aconitase activity, and ATP levels, which is in line with previous studies [35,76]. Interestingly, pre-treatment with adenosine increased the MMP and ATP levels in BSO-treated FRDA fibroblasts. Xu et al. [77] observed that 100 µM adenosine restored the MMP in Wistar rat cardiomyocytes upon exposure to H2O2. Olatunji et al. [78] also demonstrated that adenosine isolated from C. cicadae attenuated the dissipation of MMP in glutamate-induced oxidative stress in PC-12 cells. Furthermore, Kalogeris et al. [79] showed that co-incubation of 10 µM adenosine with 1 ng/mL tumor necrosis factor alpha (TNF-α) attenuated apoptosis and increased MMP and ATP levels in human microvascular endothelial cells (HMEC-1). Janier et al. [80] observed that adenosine increased ATP levels in the heart tissue of New Zealand White rabbits upon exposure to ischemia and reperfusion injuries. In contrast, adenosine did not increase the MMP in C57BL/6J mice oocytes during meiotic maturation [81].
Aconitase, an enzyme of the Krebs cycle localized in mitochondria, is a prototypical example of a multifunctional protein. It is involved in the metabolic regulation of iron for maintaining ROS homeostasis. Aconitase has been reported to be severely affected in FRDA [82]. Indeed, while the activity of the mitochondrial enzyme is determinant for the metabolic flux through the tricarboxylic acid in the mitochondria, the cytosolic counterpart of the aconitase is known to regulate the overall iron metabolism of mammalian cells tightly. Our results indicate that pre-treatment with adenosine failed to increase the aconitase activity following exposure to BSO. Likewise, Lian and Stringer [83] also observed that pre-treatment with glutamine, a precursor of glutathione, did not rescue impaired mitochondrial aconitase activity in the rat cortical astrocytes upon exposure to cortical spreading depression and fluorocitrate, an inhibitor of the Krebs cycle. Not surprisingly in view of the critical role of aconitase in cell metabolism, inactivation of mitochondrial aconitase through an oxidative post-translational mechanism may lead to severe loss of aconitase activity.
Mitochondrial proteins are encoded by either nDNA or mtDNA, with approximately 99% of proteins encoded solely by nDNA. Therefore, nDNA-encoded mitochondrial proteins are the major determinant of mitochondrial abundance and mtDNA copy number following oxidative stress [84]. In this study, we assessed mitochondrial biogenesis of the respiratory chain, which is dependent on subunits encoded by both nuclear and mtDNA genes [85,86]. There was no significant difference in the SDH-A/COX1 ratio between the negative control and FRDA fibroblasts treated with BSO, indicating BSO did not alter mitochondrial biogenesis. Similarly, Aquilano et al. [87] found that increased mitochondrial biogenesis was not affected by the depletion of glutathione (GSH) in SH-SY5Y cells exposed to BSO, as the level of mitochondrial proteins such as heat shock protein 60 (Hsp60), COX, and cytochrome c remained unchanged. Interestingly, adenosine significantly increased the SDH-A/COX1 ratio in FRDA fibroblasts treated with BSO, indicating mitochondrial biogenesis may involve nDNA-encoded mitochondrial proteins. Moreover, SDH-A acts as a mitochondrial mass marker, as it is correlated with mitochondrial porin or voltage-dependent anion channel, the most abundant mitochondrial protein found in the outer membrane [88,89]. Vincent et al. [90] observed that low expression of SDH-A resulted in low mitochondrial mass in myofibers derived from patients with myofibrillar myopathy. Kalogeris et al. [79] demonstrated that HMEC-1 cells incubated with adenosine for 1–8 days increased the levels of mitochondrial biogenesis markers and mediators, including PPARGC1A, NFE2L2, porin, and cytochrome c oxidase subunit 4 (COX4, nDNA-encoded) in a time-dependent manner.
Several key factors, such as NRF1, TFAM, PPARGC1A, and NFE2L2, have been found to modulate mitochondrial biogenesis. The PPARGC1A and NFE2L2 regulate mitochondrial biogenesis by activating NRF1, leading to enhanced expression of TFAM, which is necessary for the replication and transcription of mtDNA [91,92,93]. In this study, BSO-treated FRDA fibroblasts showed increased expression of NRF1, TFAM, and NFE2L2 but not PPARGC1A. Therefore, we postulated that BSO may induce low-level oxidative stress in FRDA fibroblasts and, thus, activates mitochondrial biogenesis through an NFE2L2 signaling cascade. Marmolino et al. [94] reported that the expression of PPARGC1A remained unchanged in FRDA primary fibroblasts following exposure to H2O2, possibly due to low-level and chronic oxidative stress induced by H2O2. Additionally, BSO depleted the level of GSH in murine embryonic fibroblasts but upregulated the level of NFE2L2, suggesting its crucial role in cellular adaptive mechanisms following oxidative stress [95]. Furthermore, Aquilano et al. [96] demonstrated that BSO-treated SH-SY5Y cells increased the gene expression and protein levels of NFE2L2, superoxide dismutase 2 (SOD2), and γ-glutamylcysteine ligase (γ-GCL).
In the present study, adenosine modulated the expression of NRF1, TFAM, and NFE2L2 and increased nDNA-encoded mitochondrial proteins involved in mitochondrial biogenesis. This is in line with the recent findings of Walsh et al. [97], demonstrating that NFE2L2 activators reduced the protein levels of NFE2L2 and glutathione reductase, whereas the combination of NRF1 and NFE2L2 activators reduced the protein levels of complex II, III, IV, and V in C2C12 myoblasts upon exposure to H2O2. Walsh et al. [97] postulated that both NRF1 and NFE2L2 work synergistically to regulate a transcriptional process to promote adaptive homeostasis in response to stressful stimuli. Accordingly, Min et al. [98] also found that adenosine-induced nuclear translocation of NFE2L2 and increased the protein levels of ARE in primary rat microglial and BV2 cells. In contrast to our observation, Kalogeris et al. [79] demonstrated an elevation of protein levels of PPARGC1A and NFE2L2 up to 1.5- to 4-fold higher compared to negative control in HMEC-1 cells following incubation with 1 µM adenosine for 2-5 days. In addition, they also revealed that adenosine could mediate the preservation of mitochondrial mass in HMEC-1 cells following TNF-α-induced apoptosis by increasing the expression of PPARGC1A.
Adenosine is a metabolite generated in response to hypoxia, injury, or inflammation, eliciting its protective or damaging responses through adenylyl cyclase inhibitory A1R and A3R and the adenylyl cyclase stimulatory A2AR and A2BR. Our observation is in line with previous findings [99,100,101]. Enhanced levels of extracellular adenosine have been reported to activate cytoprotective signaling through A1R in mediating the modulation of coronary flow, heart rate and contraction, cardioprotection, inflammatory response, cell growth, and tissue remodeling [99]. On the other hand, Castro et al. [100] demonstrated the protective effects of intraarticular injections of liposomal adenosine or A2 agonist against mitochondrial oxidized material and ROS burden in a mouse model of obesity-induced osteoarthritis. In addition, adenosine regulated metabolic functions through receptor-dependent mechanisms involving A1R and A2AR, and the formation of ROS and reactive nitrogen species in response to neuroinflammation in mixed glial cells and an animal model of neuroinflammation induced by intracerebroventricular administration of lipopolysaccharide [101].
Our findings show that adenosine possessed protective effects against BSO-induced oxidative stress and cell death in FRDA fibroblasts. Adenosine reconstructed mitochondrial function and regulated mitochondrial biogenesis, contributing to mitochondrial ROS and cellular iron homeostasis. The NRF1, TFAM, and NFE2L2 are the key regulators of mitochondrial biogenesis (Figure 7).

5. Conclusions

Our study demonstrated that adenosine targeted mitochondrial defects in FRDA, contributing to improved mitochondrial function and biogenesis, leading to cellular iron homeostasis. Therefore, we suggest a possible therapeutic role for adenosine in FRDA.

Author Contributions

Conceptualization, K.H.W.; methodology, S.Y.L. and K.H.W.; validation, S.Y.L.; formal analysis, S.Y.L.; investigation, S.Y.L., M.W.L.P. and N.S.M.H.; preparation of original draft, S.Y.L. and K.H.W.; review and editing, N.S.M.H., R.Y.Y.P., S.N.S.A.R., M.A.K., S.C.C., K.C.T. and L.W.L.; visualization, S.Y.L. and N.S.M.H.; data curation, S.Y.L.; resources, K.H.W.; funding acquisition, K.H.W.; supervision, S.H.L., L.W.L. and K.H.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Higher Education Malaysia via the Fundamental Research Grant Scheme ((FRGS/1/2022/SKK06/UM/02/5) and (FRGS/1/2016/SKK06/UM/02/8)), Private Funding (PV036-2020) and RU Geran–Fakulti Program via University of Malaya Faculty of Medicine Research Grant (GPF003C-2019). The article processing charge was funded by the Universiti Malaya Page Charge Fund.

Institutional Review Board Statement

All samples from NIGMS Repository Collection have been collected under Institutional Review Board approval and patient informed consent. These are the requirements for the samples to be part of the repository collection when the samples are submitted to Coriell Institute for Medical Research by the submitting physician or clinician.

Informed Consent Statement

All samples from NIGMS Repository Collection have been collected under Institutional Review Board approval and patient informed consent. These are the requirements for the samples to be part of the repository collection when the samples are submitted to Coriell Institute for Medical Research by the submitting physician or clinician. Links to the NIGMS collection’s pages for submitters and patients. Link to the brochure for the patients who donate samples with information about informed consent and privacy: https://www.coriell.org/0/Sections/Support/NIGMS/Brochure.aspx?PgId=226 accessed on 6 December 2022. Link to model informed consent form for the NIGMS Collection: https://www.coriell.org/1/NIGMS/Affected-Families-Donate-Here/Forms-and-Documentation accessed on 6 December 2022. Information for patients whose samples are submitted: https://www.coriell.org/1/NIGMS/About/Information-for-Patients accessed on 6 December 2022. Link to general submission guidelines: https://www.coriell.org/1/NIGMS/Affected-Families-Donate-Here/Submission-Requirements-and-Requesting-a-Kit accessed on 6 December 2022. FAQ about Human Subjects Research: https://www.coriell.org/1/NIGMS/FAQ accessed on 6 December 2022. The NIH Confidentiality Certificate now covers any NIH-funded research. Please see the NIH website (https://grants.nih.gov/policy/humansubjects/coc.htm accessed on 6 December 2022) for more information.

Data Availability Statement

Data sharing is not applicable. No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ACTBactin beta
ANOVAone-way analysis of variance
A1Radenosine A1 receptor
A2ARadenosine A2A receptor
A2BRadenosine A2B receptor
A3Radenosine A3 receptor
AREantioxidant response element
ATPadenosine triphosphate
BSOL-buthionine sulfoximine
cDNAcomplementary DNA
CNScentral nervous system
COX1cytochrome c oxidase subunit 1
CO2carbon dioxide
DMEMDulbecco’s Modified Eagle Medium
DMSOdimethyl sulfoxide
FBSfetal bovine serum
FDAFood Drug and Administration
Fe-SIron–sulfur
FRDAFriedreich’s ataxia
FXNfrataxin
GAAguanine–adenine–adenine
hhour
HMEC-1human microvascular endothelial cells
H2O2
HSD
LHON		hydrogen peroxide
Tukey’s honestly significant difference
Leber’s hereditary optic neuropathy
mMmillimolar
MMP/ΔΨmmitochondrial membrane potential
mtDNAmitochondrial DNA
MTT3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
nDNAnuclear DNA
NFE2L2
NIGMS		NFE2-like bZIP transcription factor 2
National Institute of General Medical Sciences
NRF1nuclear respiratory factor 1
PC-12rat pheochromocytoma
PPARGC1APPARG coactivator 1 alpha
RNAribonucleic acid
ROSreactive oxygen species
RT-qPCRreverse transcription quantitative real-time polymerase chain reaction
SDstandard deviation
SDH-Asuccinate dehydrogenase subunit A
TFAMtranscription factor A, mitochondrial
TNF-αtumor necrosis factor alpha
v/vvolume/volume
µMmicromolar
°Cdegree Celsius

References

  1. Dürr, A.; Cossee, M.; Agid, Y.; Campuzano, V.; Mignard, C.; Penet, C.; Mandel, J.-L.; Brice, A.; Koenig, M. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N. Engl. J. Med. 1996, 335, 1169–1175. [Google Scholar] [CrossRef] [PubMed]
  2. Rummey, C.; Farmer, J.M.; Lynch, D.R. Predictors of loss of ambulation in Friedreich’s ataxia. Eclinicalmedicine 2020, 18, 100213. [Google Scholar] [CrossRef] [Green Version]
  3. Hanson, E.; Sheldon, M.; Pacheco, B.; Alkubeysi, M.; Raizada, V. Heart disease in Friedreich’s ataxia. World J. Cardiol. 2019, 11, 1–12. [Google Scholar] [CrossRef] [PubMed]
  4. Bürk, K. Friedreich Ataxia: Current status and future prospects. Cerebellum Ataxias 2017, 4, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Campuzano, V.; Montermini, L.; Moltò, M.D.; Pianese, L.; Cossée, M.; Cavalcanti, F.; Monros, E.; Rodius, F.; Duclos, F.; Monticelli, A.; et al. Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271, 1423–1427. [Google Scholar] [CrossRef] [PubMed]
  6. Santos, R.; Lefevre, S.D.; Sliwa, D.; Seguin, A.; Camadro, J.-M.; Lesuisse, E. Friedreich ataxia: Molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid. Redox Signal. 2010, 13, 651–690. [Google Scholar] [CrossRef] [Green Version]
  7. Carletti, B.; Piemonte, F. Friedreich’s Ataxia: A neuronal point of view on the oxidative stress hypothesis. Antioxidants 2014, 3, 592–603. [Google Scholar] [CrossRef] [Green Version]
  8. Lupoli, F.; Vannocci, T.; Longo, G.; Niccolai, N.; Pastore, A. The role of oxidative stress in Friedreich’s ataxia. FEBS Lett. 2018, 592, 718–727. [Google Scholar] [CrossRef]
  9. Llorens, J.V.; Soriano, S.; Calap-Quintana, P.; Gonzalez-Cabo, P.; Moltó, M.D. The role of iron in Friedreich’s ataxia: Insights from studies in human tissues and cellular and animal models. Front. Neurosci. 2019, 13, 75. [Google Scholar] [CrossRef] [Green Version]
  10. Pandolfo, M.; Pastore, A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 2009, 256, 9–17. [Google Scholar] [CrossRef]
  11. Armstrong, J.S.; Khdour, O.; Hecht, S.M. Does oxidative stress contribute to the pathology of Friedreich’s ataxia? A radical question. FASEB J. 2010, 24, 2152–2163. [Google Scholar] [CrossRef]
  12. Bolotta, A.; Pini, A.; Abruzzo, P.M.; Ghezzo, A.; Modesti, A.; Gamberi, T.; Ferreri, C.; Bugamelli, F.; Fortuna, F.; Vertuani, S.; et al. Effects of tocotrienol supplementation in Friedreich’s ataxia: A model of oxidative stress pathology. Exp. Biol. Med. 2020, 245, 201–212. [Google Scholar] [CrossRef] [Green Version]
  13. Lynch, D.R.; Farmer, G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: Update on pathophysiological relevance and clinical interventions. Neuronal Signal. 2021, 5, NS20200093. [Google Scholar] [CrossRef] [PubMed]
  14. Liu, Y.; Chen, J.; Li, X.; Zhou, X.; Hu, Y.; Chu, S.; Peng, Y.; Chen, N. Research progress on adenosine in central nervous system diseases. CNS Neurosci. Ther. 2019, 25, 899–910. [Google Scholar] [CrossRef] [PubMed]
  15. Qi, G.; van Aerde, K.; Abel, T.; Feldmeyer, D. Adenosine differentially modulates synaptic transmission of excitatory and inhibitory microcircuits in layer 4 of rat barrel cortex. Cereb. Cortex 2017, 27, 4411–4422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Ziganshin, A.; Khairullin, A.; Hoyle, C.; Grishin, S. Modulatory roles of ATP and adenosine in cholinergic neuromuscular transmission. Int. J. Mol. Sci. 2020, 21, 6423. [Google Scholar] [CrossRef]
  17. Van Aerde, K.I.; Qi, G.; Feldmeyer, D. Cell type-specific effects of adenosine on cortical neurons. Cereb. Cortex 2015, 25, 772–787. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Zhang, M.; Vollmer, C.; Nurse, C.A. Adenosine and dopamine oppositely modulate a hyperpolarization-activated currentIhin chemosensory neurons of the rat carotid body in co-culture. J. Physiol. 2018, 596, 3101–3117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Boison, D.; Singer, P.; Shen, H.-Y.; Feldon, J.; Yee, B.K. Adenosine hypothesis of schizophrenia—Opportunities for pharmacotherapy. Neuropharmacology 2012, 62, 1527–1543. [Google Scholar] [CrossRef] [Green Version]
  20. Fredholm, B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007, 14, 1315–1323. [Google Scholar] [CrossRef] [Green Version]
  21. Van Calker, D.; Biber, K.; Domschke, K.; Serchov, T. The role of adenosine receptors in mood and anxiety disorders. J. Neurochem. 2019, 151, 11–27. [Google Scholar] [CrossRef] [Green Version]
  22. Melani, A.; Pugliese, A.M.; Pedata, F. Adenosine receptors in cerebral ischemia. Int. Rev. Neurobiol. 2014, 119, 309–348. [Google Scholar] [CrossRef] [PubMed]
  23. Coelho, J.E.; Alves, P.; Canas, P.M.; Valadas, J.S.; Shmidt, T.; Batalha, V.L.; Ferreira, D.G.; Ribeiro, J.A.; Bader, M.; Cunha, R.A.; et al. Overexpression of adenosine A2A receptors in rats: Effects on depression, locomotion, and anxiety. Front. Psychiatry 2014, 5, 67. [Google Scholar] [CrossRef] [Green Version]
  24. Chen, J.-F. Chapter twelve – Adenosine receptor control of cognition in normal and disease. Int. Rev. Neurobiol. 2014, 119, 257–307. [Google Scholar] [CrossRef]
  25. Kao, Y.-H.; Lin, M.-S.; Chen, C.-M.; Wu, Y.-R.; Chen, H.-M.; Lai, H.-L.; Chern, Y.; Lin, C.-J. Targeting ENT1 and adenosine tone for the treatment of Huntington’s disease. Hum. Mol. Genet. 2017, 26, 467–478. [Google Scholar] [CrossRef]
  26. Lee, C.-C.; Chang, C.-P.; Lin, C.-J.; Lai, H.-L.; Kao, Y.-H.; Cheng, S.-J.; Chen, H.-M.; Liao, Y.-P.; Faivre, E.; Buée, L.; et al. Adenosine augmentation evoked by an ENT1 inhibitor improves memory impairment and neuronal plasticity in the APP/PS1 mouse model of Alzheimer’s disease. Mol. Neurobiol. 2018, 55, 8936–8952. [Google Scholar] [CrossRef] [PubMed]
  27. Chen, J.-F.; Cunha, R.A. The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease. Purinergic Signal. 2020, 16, 167–174. [Google Scholar] [CrossRef]
  28. Jenner, P.; Mori, A.; Aradi, S.D.; Hauser, R.A. Istradefylline—A first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Rev. Neurother. 2021, 21, 317–333. [Google Scholar] [CrossRef] [PubMed]
  29. Chang, C.-P.; Wu, K.-C.; Lin, C.-Y.; Chern, Y. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. J. Biomed. Sci. 2021, 28, 70. [Google Scholar] [CrossRef]
  30. Heffner, T.G.; Wiley, J.N.; Williams, A.E.; Bruns, R.F.; Coughenour, L.L.; Downs, D.A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 1989, 98, 31–37. [Google Scholar] [CrossRef]
  31. Dar, M.S. Central adenosinergic system involvement in ethanol-induced motor incoordination in mice. J. Pharmacol. Exp. Ther. 1990, 255, 1202–1209. [Google Scholar]
  32. Dar, M. Cerebellar CB1 receptor mediation of Δ9-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A1 receptor in the mouse. Brain Res. 2000, 864, 186–194. [Google Scholar] [CrossRef] [PubMed]
  33. DeSanty, K.P.; Dar, M. Involvement of the cerebellar adenosine A1 receptor in cannabinoid-induced motor incoordination in the acute and tolerant state in mice. Brain Res. 2001, 905, 178–187. [Google Scholar] [CrossRef]
  34. Dar, M.; Mustafa, S. Acute ethanol/cannabinoid-induced ataxia and its antagonism by oral/systemic/intracerebellar A1 adenosine receptor antisense in mice. Brain Res. 2002, 957, 53–60. [Google Scholar] [CrossRef] [PubMed]
  35. Richardson, T.E.; Yu, A.E.; Wen, Y.; Yang, S.-H.; Simpkins, J.W. Estrogen prevents oxidative damage to the mitochondria in Friedreich’s ataxia skin fibroblasts. PLoS ONE 2012, 7, e34600. [Google Scholar] [CrossRef] [PubMed]
  36. Jauslin, M.L.; Wirth, T.; Meier, T.; Schoumacher, F. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum. Mol. Genet. 2002, 11, 3055–3063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Jauslin, M.L.; Vertuani, S.; Durini, E.; Buzzoni, L.; Ciliberti, N.; Verdecchia, S.; Palozza, P.; Meier, T.; Manfredini, S. Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia. Mol. Cell Biochem. 2007, 302, 79–85. [Google Scholar] [CrossRef] [PubMed]
  38. Lew, S.-Y.; Yow, Y.-Y.; Lim, L.-W.; Wong, K.-H. Antioxidant-mediated protective role of Hericium erinaceus (Bull.: Fr.) Pers. against oxidative damage in fibroblasts from Friedreich’s ataxia patient. Food Sci. Technol. 2020, 40 (Suppl. 1), 264–272. [Google Scholar] [CrossRef] [Green Version]
  39. Igarashi, J.; Okamoto, R.; Yamashita, T.; Hashimoto, T.; Karita, S.; Nakai, K.; Kubota, Y.; Takata, M.; Yamaguchi, F.; Tokuda, M.; et al. A key role of PGC-1α transcriptional coactivator in production of VEGF by a novel angiogenic agent COA-Cl in cultured human fibroblasts. Physiol. Rep. 2016, 4, e12742. [Google Scholar] [CrossRef]
  40. Jasoliya, M.J.; McMackin, M.Z.; Henderson, C.K.; Perlman, S.L.; Cortopassi, G.A. Frataxin deficiency impairs mitochondrial biogenesis in cells, mice and humans. Hum. Mol. Genet. 2017, 26, 2627–2633. [Google Scholar] [CrossRef] [Green Version]
  41. Cheng, X.; Qian, W.; Chen, F.; Jin, Y.; Wang, F.; Lu, X.; Lee, S.R.; Su, D.; Chen, B. ATRA protects skin fibroblasts against UV-induced oxidative damage through inhibition of E3 ligase Hrd1. Mol. Med. Rep. 2019, 20, 2294–2302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Oh, S.; Lee, M.-S.; Jung, S.; Kim, S.; Park, H.; Park, S.; Kim, S.-Y.; Kim, C.-T.; Jo, Y.-H.; Kim, I.-H.; et al. Ginger extract increases muscle mitochondrial biogenesis and serum HDL-cholesterol level in high-fat diet-fed rats. J. Funct. Foods 2017, 29, 193–200. [Google Scholar] [CrossRef]
  43. Kwong, S.C.; Jamil, A.H.A.; Rhodes, A.; Taib, N.A.; Chung, I. Metabolic role of fatty acid binding protein 7 in mediating triple-negative breast cancer cell death via PPAR-α signaling. J. Lipid Res. 2019, 60, 1807–1817. [Google Scholar] [CrossRef] [PubMed]
  44. Cook, A.; Giunti, P. Friedreich’s ataxia: Clinical features, pathogenesis and management. Br. Med. Bull. 2017, 124, 19–30. [Google Scholar] [CrossRef] [PubMed]
  45. Chong, P.S.; Poon, C.H.; Roy, J.; Tsui, K.C.; Lew, S.Y.; Phang, M.W.L.; Tan, R.J.Y.; Cheng, P.G.; Fung, M.-L.; Wong, K.H.; et al. Neurogenesis-dependent antidepressant-like activity of Hericium erinaceus in an animal model of depression. Chin. Med. 2021, 16, 132. [Google Scholar] [CrossRef]
  46. Samberkar, S.; Gandhi, S.; Naidu, M.; Wong, K.-H.; Raman, J.; Sabaratnam, V. Lion’s mane, Hericium erinaceus and Tiger milk, Lignosus rhinocerotis (higher basidiomycetes) medicinal mushrooms stimulate neurite outgrowth in dissociated cells of brain, spinal cord, and retina: An in vitro study. Int. J. Med. Mushrooms 2015, 17, 1047–1054. [Google Scholar] [CrossRef] [Green Version]
  47. Wong, K.-H.; Ng, C.-C.; Kanagasabapathy, G.; Yow, Y.-Y.; Sabaratnam, V. An Overview of culinary and medicinal mushrooms in neurodegeneration and neurotrauma research. Int. J. Med. Mushrooms 2017, 19, 191–202. [Google Scholar] [CrossRef]
  48. Lew, S.Y.; Lim, S.H.; Lim, L.W.; Wong, K.H. Neuroprotective effects of Hericium erinaceus (Bull.: Fr.) Pers. against high-dose corticosterone-induced oxidative stress in PC-12 cells. BMC Complement. Med. Ther. 2020, 20, 340. [Google Scholar] [CrossRef]
  49. Lin, T.S.; Woon, C.K.; Hui, W.K.; Abas, R.; Haron, M.H.; Das, S. Natural product-based nanomedicine: Recent advances and issues for the treatment of Alzheimer’s disease. Curr. Neuropharmacol. 2022, 20, 1498–1518. [Google Scholar] [CrossRef]
  50. Yanshree; Yu, W.S.; Fung, M.L.; Lee, C.W.; Lim, L.W.; Wong, K.H. The monkey head mushroom and memory enhancement in Alzheimer’s disease. Cells 2020, 11, 2284. [Google Scholar] [CrossRef]
  51. Lew, S.Y.; Phang, M.W.L.; Chong, P.S.; Roy, J.; Poon, C.H.; Yu, W.S.; Lim, L.W.; Wong, K.H. Discovery of therapeutics targeting oxidative stress in autosomal recessive cerebellar ataxia: A systematic review. Pharmaceuticals 2022, 15, 764. [Google Scholar] [CrossRef] [PubMed]
  52. Chong, P.S.; Khairuddin, S.; Tse, A.C.K.; Hiew, L.F.; Lau, C.L.; Tipoe, G.L.; Fung, M.-L.; Wong, K.H.; Lim, L.W. Hericium erinaceus potentially rescues behavioural motor deficits through ERK-CREB-PSD95 neuroprotective mechanisms in rat model of 3-acetylpyridine-induced cerebellar ataxia. Sci. Rep. 2020, 10, 14945. [Google Scholar] [CrossRef] [PubMed]
  53. Phang, M.W.L.; Lew, S.Y.; Chung, I.; Lim, W.K.-S.; Lim, L.W.; Wong, K.H. Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review. Chin. Med. 2021, 16, 15. [Google Scholar] [CrossRef] [PubMed]
  54. Valdes, F.; Brown, N.; Morales-Bayuelo, A.; Prent-Peñaloza, L.; Gutierrez, M. Adenosine derivates as antioxidant agents: Synthesis, characterization, in vitro activity, and theoretical insights. Antioxidants 2019, 8, 468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Gholinejad, M.; Anarkooli, I.J.; Taromchi, A.; Abdanipour, A. Adenosine decreases oxidative stress and protects H2O2-treated neural stem cells against apoptosis through decreasing Mst1 expression. Biomed. Rep. 2018, 8, 439–446. [Google Scholar] [CrossRef] [Green Version]
  56. Gueven, N.; Woolley, K.; Smith, J. Border between natural product and drug: Comparison of the related benzoquinones idebenone and coenzyme Q10. Redox Biol. 2015, 4, 289–295. [Google Scholar] [CrossRef] [Green Version]
  57. Jaber, S.; Polster, B.M. Idebenone and neuroprotection: Antioxidant, pro-oxidant, or electron carrier? J. Bioenerg. Biomembr. 2015, 47, 111–118. [Google Scholar] [CrossRef] [Green Version]
  58. Mercuri, E.; Muntoni, F. Efficacy of idebenone in Duchenne muscular dystrophy. Lancet 2015, 385, 1704–1706. [Google Scholar] [CrossRef]
  59. Nohara, Y.; Suzuki, J.; Yamazaki, Y.; Kubo, H. Determination of idebenone in plasma by HPLC with post-column fluorescence derivatization using 2-cyanoacetamide. Chem. Pharm. Bull. 2012, 60, 598–602. [Google Scholar] [CrossRef] [Green Version]
  60. Giorgio, V.; Schiavone, M.; Galber, C.; Carini, M.; Da Ros, T.; Petronilli, V.; Argenton, F.; Carelli, V.; Lopez, M.J.A.; Salviati, L.; et al. The idebenone metabolite QS10 restores electron transfer in complex I and coenzyme Q defects. Biochim. Biophys. Acta (BBA) Bioenerg. 2018, 1859, 901–908. [Google Scholar] [CrossRef]
  61. Rustin, P.; von Kleist-Retzow, J.-C.; Chantrel-Groussard, K.; Sidi, D.; Munnich, A.; Rötig, A. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: A preliminary study. Lancet 1999, 354, 477–479. [Google Scholar] [CrossRef]
  62. Seznec, H.; Simon, D.; Monassier, L.; Criqui-Filipe, P.; Gansmuller, A.; Rustin, P.; Koenig, M.; Puccio, H. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet. 2004, 13, 1017–1024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Soriano, S.; Llorens, J.V.; Blanco-Sobero, L.; Gutiérrez, L.; Calap-Quintana, P.; Morales, M.P.; Moltó, M.D.; Martínez-Sebastián, M.J. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich’s ataxia. Gene 2013, 521, 274–281. [Google Scholar] [CrossRef] [Green Version]
  64. Calap-Quintana, P.; Soriano, S.; Llorens, J.V.; Al-Ramahi, I.; Botas, J.; Moltó, M.D.; Martínez-Sebastián, M.J. TORC1 inhibition by rapamycin promotes antioxidant defences in a Drosophila model of Friedreich’s ataxia. PLoS ONE 2015, 10, e0132376. [Google Scholar] [CrossRef] [PubMed]
  65. Petrillo, S.; D’Amico, J.; La Rosa, P.; Bertini, E.S.; Piemonte, F. Targeting NRF2 for the treatment of Friedreich’s ataxia: A comparison among drugs. Int. J. Mol. Sci. 2019, 20, 5211. [Google Scholar] [CrossRef] [Green Version]
  66. Di Prospero, N.A.; Baker, A.; Jeffries, N.; Fischbeck, K.H. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: A randomised, placebo-controlled trial. Lancet Neurol. 2007, 6, 878–886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Lynch, D.R.; Perlman, S.L.; Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 2010, 67, 941–947. [Google Scholar] [CrossRef]
  68. Lagedrost, S.J.; Sutton, M.S.J.; Cohen, M.S.; Satou, G.M.; Kaufman, B.D.; Perlman, S.L.; Rummey, C.; Meier, T.; Lynch, D.R. Idebenone in Friedreich ataxia cardiomyopathy—Results from a 6-month phase III study (IONIA). Am. Heart J. 2011, 161, 639–645.e1. [Google Scholar] [CrossRef]
  69. Meier, T.; Perlman, S.L.; Rummey, C.; Coppard, N.J.; Lynch, D.R. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: Data from a 6-month controlled study followed by a 12-month open-label extension study. J. Neurol. 2012, 259, 284–291. [Google Scholar] [CrossRef]
  70. Paredes-Fuentes, A.J.; Cesar, S.; Montero, R.; Latre, C.; Genovès, J.; Martorell, L.; Cuadras, D.; Colom, H.; Pineda, M.; O’Callaghan, M.D.M.; et al. Plasma idebenone monitoring in Friedreich’s ataxia patients during a long-term follow-up. Biomed. Pharmacother. 2021, 143, 112143. [Google Scholar] [CrossRef]
  71. Barth, A.; Newell, D.W.; Nguyen, L.B.; Winn, H.; Wender, R.; Meno, J.R.; Janigro, D. Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res. 1997, 762, 79–88. [Google Scholar] [CrossRef]
  72. Jennings, J.A. Locally delivered adenosine and glutathione improve fibroblast proliferation and collagen production. Biomed. Eng. Rev. 2015, 2, 1–22. Available online: https://esmed.org/MRA/bme/article/view/167 (accessed on 6 December 2022).
  73. Ouyang, X.; Ghani, A.; Malik, A.; Wilder, T.; Colegio, O.R.; Flavell, R.A.; Cronstein, B.N.; Mehal, W.Z. Adenosine is required for sustained inflammasome activation via the A2A receptor and the HIF-1α pathway. Nat. Commun. 2013, 4, 2909. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Bansal, Y.; Kuhad, A. Mitochondrial dysfunction in depression. Curr. Neuropharmacol. 2016, 14, 610–618. [Google Scholar] [CrossRef] [Green Version]
  75. Konishi, H.; Kanou, S.-E.; Yukimatsu, R.; Inui, M.; Sato, M.; Yamamoto, N.; Nakano, M.; Koshiba, M. Adenosine inhibits TNFα-induced MMP-3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling. Sci. Rep. 2022, 12, 6033. [Google Scholar] [CrossRef]
  76. García-Giménez, J.L.; Gimeno, A.; Gonzalez-Cabo, P.; Dasí, F.; Bolinches-Amorós, A.; Mollá, B.; Palau, F.; Pallardó, F.V. Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts. PLoS ONE 2011, 6, e20666. [Google Scholar] [CrossRef] [Green Version]
  77. Xu, Z.; Park, S.-S.; Mueller, R.A.; Bagnell, R.C.; Patterson, C.; Boysen, P.G. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc. Res. 2005, 65, 803–812. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Olatunji, O.J.; Feng, Y.; Olatunji, O.O.; Tang, J.; Ouyang, Z.; Su, Z.; Wang, D.; Yu, X. Neuroprotective effects of adenosine isolated from Cordyceps cicadae against oxidative and ER stress damages induced by glutamate in PC12 cells. Environ. Toxicol. Pharmacol. 2016, 44, 53–61. [Google Scholar] [CrossRef] [PubMed]
  79. Kalogeris, T.J.; Baines, C.; Korthuis, R.J. Adenosine prevents TNFα-induced decrease in endothelial mitochondrial mass via activation of eNOS-PGC-1α regulatory axis. PLoS ONE 2014, 9, e98459. [Google Scholar] [CrossRef] [Green Version]
  80. Janier, M.; Vanoverschelde, J.L.; Bergmann, S.R. Adenosine protects ischemic and reperfused myocardium by receptor-mediated mechanisms. Am. J. Physiol. Circ. Physiol. 1993, 264, H163–H170. [Google Scholar] [CrossRef]
  81. Fujii, W.; Funahashi, H. Exogenous adenosine reduces the mitochondrial membrane potential of murine oocytes during the latter half of in vitro maturation and pronuclear formation following chemical activation. J. Reprod. Dev. 2009, 55, 187–193. [Google Scholar] [CrossRef] [Green Version]
  82. Delatycki, M.B.; Williamson, R.; Forrest, S.M. Friedreich ataxia: An overview. J. Med. Genet. 2000, 37, 1–8. [Google Scholar] [CrossRef] [PubMed]
  83. Lian, X.-Y.; Stringer, J.L. Energy failure in astrocytes increases the vulnerability of neurons to spreading depression. Eur. J. Neurosci. 2004, 19, 2446–2454. [Google Scholar] [CrossRef] [PubMed]
  84. Pfanner, N.; Warscheid, B.; Wiedemann, N. Mitochondrial proteins: From biogenesis to functional networks. Nat. Rev. Mol. Cell Biol. 2019, 20, 267–284. [Google Scholar] [CrossRef]
  85. Augustyniak, J.; Lenart, J.; Zychowicz, M.; Stepien, P.P.; Buzanska, L. Mitochondrial biogenesis and neural differentiation of human iPSC is modulated by idebenone in a developmental stage-dependent manner. Biogerontology 2017, 18, 665–677. [Google Scholar] [CrossRef] [Green Version]
  86. Khdour, O.M.; Bandyopadhyay, I.; Visavadiya, N.P.; Chowdhury, S.R.; Hecht, S.M. Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich’s ataxia cells. MedChemComm 2018, 9, 1491–1501. [Google Scholar] [CrossRef] [PubMed]
  87. Aquilano, K.; Baldelli, S.; Cardaci, S.; Rotilio, G.; Ciriolo, M.R. Nitric oxide is the primary mediator of cytotoxicity induced by GSH depletion in neuronal cells. J. Cell Sci. 2011, 124, 1043–1054. [Google Scholar] [CrossRef] [Green Version]
  88. Rocha, M.C.; Grady, J.P.; Grünewald, A.; Vincent, A.; Dobson, P.F.; Taylor, R.W.; Turnbull, D.M.; Rygiel, K.A. A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: Understanding mechanisms and improving diagnosis. Sci. Rep. 2015, 5, 15037. [Google Scholar] [CrossRef] [Green Version]
  89. Vincent, A.E.; Rosa, H.S.; Pabis, K.; Lawless, C.; Chen, C.; Grünewald, A.; Rygiel, K.A.; Rocha, M.C.; Reeve, A.K.; Falkous, G.; et al. Subcellular origin of mitochondrial DNA deletions in human skeletal muscle. Ann. Neurol. 2018, 84, 289–301. [Google Scholar] [CrossRef] [Green Version]
  90. Vincent, A.E.; Grady, J.P.; Rocha, M.C.; Alston, C.L.; Rygiel, K.A.; Barresi, R.; Taylor, R.W.; Turnbull, D.M. Mitochondrial dysfunction in myofibrillar myopathy. Neuromuscul. Disord. 2016, 26, 691–701. [Google Scholar] [CrossRef] [Green Version]
  91. Gordon, J.W.; Rungi, A.A.; Inagaki, H.; Hood, D.A. Selected Contribution: Effects of contractile activity on mitochondrial transcription factor A expression in skeletal muscle. J. Appl. Physiol. 2001, 90, 389–396. [Google Scholar] [CrossRef] [PubMed]
  92. Li, P.A.; Hou, X.; Hao, S. Mitochondrial biogenesis in neurodegeneration. J. Neurosci. Res. 2017, 95, 2025–2029. [Google Scholar] [CrossRef] [PubMed]
  93. Virbasius, J.V.; Scarpulla, R.C. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: A potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 1309–1313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Marmolino, D.; Manto, M.; Acquaviva, F.; Vergara, P.; Ravella, A.; Monticelli, A.; Pandolfo, M. PGC-1alpha down-regulation affects the antioxidant response in Friedreich’s ataxia. PLoS ONE 2010, 5, e10025. [Google Scholar] [CrossRef] [PubMed]
  95. Lee, H.-R.; Cho, J.-M.; Shin, D.-H.; Yong, C.S.; Choi, H.-G.; Wakabayashi, N.; Kwak, M.-K. Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: Involvement of Nrf2 activation. Mol. Cell Biochem. 2008, 318, 23–31. [Google Scholar] [CrossRef]
  96. Aquilano, K.; Baldelli, S.; Pagliei, B.; Cannata, S.M.; Rotilio, G.; Ciriolo, M.R. p53 orchestrates the PGC-1α-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid. Redox Signal. 2013, 18, 386–399. [Google Scholar] [CrossRef] [Green Version]
  97. Walsh, M.A.; Zhang, Q.; Musci, R.V.; Hamilton, K.L. The combination of NRF1 and Nrf2 activators in myoblasts stimulate mechanisms of proteostasis without changes in mitochondrial respiration. Redox Muscle Physiol. Exerc. Sport 2022, 1, 100001. [Google Scholar] [CrossRef]
  98. Min, K.-J.; Kim, J.-H.; Jou, I.; Joe, E.-H. Adenosine induces hemeoxygenase-1 expression in microglia through the activation of phosphatidylinositol 3-kinase and nuclear factor E2-related factor 2. Glia 2008, 56, 1028–1037. [Google Scholar] [CrossRef]
  99. Sheth, S.; Brito, R.; Mukherjea, D.; Rybak, L.P.; Ramkumar, V. Adenosine receptors: Expression, function and regulation. Int. J. Mol. Sci. 2014, 15, 2024–2052. [Google Scholar] [CrossRef] [Green Version]
  100. Castro, C.M.; Corciulo, C.; Solesio, M.E.; Liang, F.; Pavlov, E.V.; Cronstein, B.N. Adenosine A2A receptor (A2AR) stimulation enhances mitochondrial metabolism and mitigates reactive oxygen species-mediated mitochondrial injury. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2020, 34, 5027–5045. [Google Scholar] [CrossRef] [Green Version]
  101. Navia, A.M.; Ben, D.D.; Lambertucci, C.; Spinaci, A.; Volpini, R.; Coelho, J.E.; Lopes, L.V.; Marques-Morgado, I.; Marucci, G.; Buccioni, M. Adenosine receptors as neuroinflammation modulators: Role of A1 agonists and A2A antagonists. Cells 2020, 9, 1739. [Google Scholar] [CrossRef] [PubMed]
Biology 12 00559 g001 550
Figure 1. Effects of adenosine on the viability of normal and FRDA fibroblasts. Cell viability was evaluated by MTT assay following incubation with various concentrations of adenosine for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Asterisk (*) and hash sign (#) indicate significant differences (p < 0.05) in viability for different groups of normal and FRDA fibroblasts, respectively, compared to the negative control group.
Figure 1. Effects of adenosine on the viability of normal and FRDA fibroblasts. Cell viability was evaluated by MTT assay following incubation with various concentrations of adenosine for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Asterisk (*) and hash sign (#) indicate significant differences (p < 0.05) in viability for different groups of normal and FRDA fibroblasts, respectively, compared to the negative control group.
Biology 12 00559 g001
Biology 12 00559 g002 550
Figure 2. Effects of adenosine on the MMP in FRDA fibroblasts treated with BSO. The MMP was evaluated following pre-treatment with adenosine (0 to 800 µM) for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in MMP compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine; MMP, mitochondrial membrane potential.
Figure 2. Effects of adenosine on the MMP in FRDA fibroblasts treated with BSO. The MMP was evaluated following pre-treatment with adenosine (0 to 800 µM) for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in MMP compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine; MMP, mitochondrial membrane potential.
Biology 12 00559 g002
Biology 12 00559 g003 550
Figure 3. Effects of adenosine on the aconitase activity in FRDA fibroblasts treated with BSO. Aconitase activity was evaluated following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in aconitase activity compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine.
Figure 3. Effects of adenosine on the aconitase activity in FRDA fibroblasts treated with BSO. Aconitase activity was evaluated following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in aconitase activity compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine.
Biology 12 00559 g003
Biology 12 00559 g004 550
Figure 4. Effects of adenosine on the ATP level in FRDA fibroblasts treated with BSO. The ATP level was evaluated following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in ATP level compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. ATP, adenosine triphosphate; BSO, L-buthionine sulfoximine.
Figure 4. Effects of adenosine on the ATP level in FRDA fibroblasts treated with BSO. The ATP level was evaluated following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in ATP level compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. ATP, adenosine triphosphate; BSO, L-buthionine sulfoximine.
Biology 12 00559 g004
Biology 12 00559 g005 550
Figure 5. Effects of adenosine on the mitochondrial biogenesis in FRDA fibroblasts treated with BSO. Mitochondrial biogenesis was evaluated following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in the SDH-A/COX1 ratio compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine; COX1, cytochrome c oxidase subunit 1; SDH-A, succinate dehydrogenase subunit A.
Figure 5. Effects of adenosine on the mitochondrial biogenesis in FRDA fibroblasts treated with BSO. Mitochondrial biogenesis was evaluated following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Tukey’s post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in the SDH-A/COX1 ratio compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine; COX1, cytochrome c oxidase subunit 1; SDH-A, succinate dehydrogenase subunit A.
Biology 12 00559 g005
Biology 12 00559 g006 550
Figure 6. Effects of adenosine on the relative gene expressions associated with mitochondrial biogenesis in FRDA fibroblasts treated with BSO. Gene expressions of (A) NRF1, (B) TFAM, (C) PPARGC1A, and (D) NFE2L2 were evaluated by RT-qPCR following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Games–Howell post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in the relative gene expressions compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine; NFE2L2, nuclear factor-erythroid 2-related factor 2; NRF1, nuclear respiratory factor 1; PPARGC1A, PPARG coactivator 1 alpha; TFAM, transcription factor A, mitochondrial.
Figure 6. Effects of adenosine on the relative gene expressions associated with mitochondrial biogenesis in FRDA fibroblasts treated with BSO. Gene expressions of (A) NRF1, (B) TFAM, (C) PPARGC1A, and (D) NFE2L2 were evaluated by RT-qPCR following pre-treatment with adenosine for 2 h and 12.50 mM BSO for 24 h. Data are expressed as mean ± SD and statistically analyzed by one-way ANOVA with Games–Howell post-hoc test. Hash (#) and asterisk (*) indicate significant differences (p < 0.05) in the relative gene expressions compared to the idebenone group and BSO-treated (0 µM adenosine) group, respectively. BSO, L-buthionine sulfoximine; NFE2L2, nuclear factor-erythroid 2-related factor 2; NRF1, nuclear respiratory factor 1; PPARGC1A, PPARG coactivator 1 alpha; TFAM, transcription factor A, mitochondrial.
Biology 12 00559 g006
Biology 12 00559 g007 550
Figure 7. Proposed mechanism in which adenosine improves mitochondrial function and biogenesis in FRDA fibroblasts following BSO-induced oxidative stress. Illustration was created using Microsoft PowerPoint Professional Plus 2019. ATP, adenosine triphosphate; BSO, L-buthionine sulfoximine; COX1, cytochrome c oxidase subunit 1; Fe-S, iron–sulfur; FXN, frataxin; GSH, glutathione; mtDNA, mitochondrial DNA; NFE2L2, NFE2-like bZIP transcription factor 2; NRF1, nuclear respiratory factor 1; PPARGC1A, PPARG coactivator 1 alpha; ROS, reactive oxygen species; SDH-A, succinate dehydrogenase subunit A; TFAM, transcription factor A, mitochondrial; ΔΨm, mitochondrial membrane potential.
Figure 7. Proposed mechanism in which adenosine improves mitochondrial function and biogenesis in FRDA fibroblasts following BSO-induced oxidative stress. Illustration was created using Microsoft PowerPoint Professional Plus 2019. ATP, adenosine triphosphate; BSO, L-buthionine sulfoximine; COX1, cytochrome c oxidase subunit 1; Fe-S, iron–sulfur; FXN, frataxin; GSH, glutathione; mtDNA, mitochondrial DNA; NFE2L2, NFE2-like bZIP transcription factor 2; NRF1, nuclear respiratory factor 1; PPARGC1A, PPARG coactivator 1 alpha; ROS, reactive oxygen species; SDH-A, succinate dehydrogenase subunit A; TFAM, transcription factor A, mitochondrial; ΔΨm, mitochondrial membrane potential.
Biology 12 00559 g007
Table
Table 1. RT-qPCR primers.
Table 1. RT-qPCR primers.
GeneOrigin5′–3′ Primer Sequence
NFE2L2HumanForward: ACA CGG TCC ACA GCT CAT C
Reverse: TGT CAA TCA AAT CCA TGT CCT G
NRF1HumanForward: AGG AAC ACG GAG TGA CCC AA
Reverse: TAT GCT CGG TGT AAG TAG CCA
PPARGC1AHumanForward: TTG ACT GGC GTC ATT CAG GA
Reverse: GGG CAA TCC GTC TTC ATC CA
TFAMHumanForward: GTG ATT CAC CGC AGG AAA AGC
Reverse: GTG CGA CGT AGA AGA TCC TTT C
ACTBHumanForward: GCC AAC ACA GTG CTG TCT GG
Reverse: CTG CTT GCT GAT CCA CAT CTG C
ACTB, actin beta; NFE2L2, NFE2-like bZIP transcription factor 2; NRF1, nuclear respiratory factor 1; PPARGC1A PPARG coactivator 1 alpha; TFAM, transcription factor A, mitochondrial.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lew, S.Y.; Mohd Hisam, N.S.; Phang, M.W.L.; Syed Abdul Rahman, S.N.; Poh, R.Y.Y.; Lim, S.H.; Kamaruzzaman, M.A.; Chau, S.C.; Tsui, K.C.; Lim, L.W.; et al. Adenosine Improves Mitochondrial Function and Biogenesis in Friedreich's Ataxia Fibroblasts Following L-Buthionine Sulfoximine-Induced Oxidative Stress. Biology 2023, 12, 559. https://doi.org/10.3390/biology12040559

AMA Style

Lew SY, Mohd Hisam NS, Phang MWL, Syed Abdul Rahman SN, Poh RYY, Lim SH, Kamaruzzaman MA, Chau SC, Tsui KC, Lim LW, et al. Adenosine Improves Mitochondrial Function and Biogenesis in Friedreich's Ataxia Fibroblasts Following L-Buthionine Sulfoximine-Induced Oxidative Stress. Biology. 2023; 12(4):559. https://doi.org/10.3390/biology12040559

Chicago/Turabian Style

Lew, Sze Yuen, Nur Shahirah Mohd Hisam, Michael Weng Lok Phang, Syarifah Nur Syed Abdul Rahman, Rozaida Yuen Ying Poh, Siew Huah Lim, Mohd Amir Kamaruzzaman, Sze Chun Chau, Ka Chun Tsui, Lee Wei Lim, and et al. 2023. "Adenosine Improves Mitochondrial Function and Biogenesis in Friedreich's Ataxia Fibroblasts Following L-Buthionine Sulfoximine-Induced Oxidative Stress" Biology 12, no. 4: 559. https://doi.org/10.3390/biology12040559

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop